论文部分内容阅读
我国慢性乙型肝炎负担严重,估计慢性乙型肝炎为9000万例,其中700万例为慢性乙型肝炎引起的进展期肝病和肝癌高危患者,他们急需治疗。但目前仅约10%慢性乙型肝炎患者接受抗病毒治疗。为了提高慢性乙型肝炎患者抗病毒治疗的可及性,应降低抗病毒药物的价格、将抗病毒药物纳入国家基本药物目录,以及住院和门诊慢性乙型肝炎患者可医保报销,并采取药物降价机制如驳回某些影响公共卫生和医保政策的国外药品专利注册、启动政府与药厂谈判统一的药品价格等。
Chronic hepatitis B is a serious burden in our country. It is estimated that 90 million cases of chronic hepatitis B, of which 7 million cases are advanced liver disease and liver cancer caused by chronic hepatitis B, are in urgent need of treatment. However, only about 10% of patients with chronic hepatitis B receive antiretroviral therapy. In order to improve access to anti-retroviral therapy in patients with chronic hepatitis B, the price of antiviral drugs should be lowered, anti-retroviral drugs should be included in the national essential medicines list, and reimbursement should be provided for medical insurance for inpatients and outpatients with chronic hepatitis B Mechanisms such as rejecting some registration of foreign pharmaceutical patents that affect public health and health insurance policies and launching negotiations between the government and pharmaceutical companies on uniform drug prices.